Ifenprodil

• Description :

  Ifenprodil (NP-120), a cerebral vasodilator, is a noncompetitive NMDA receptor antagonist. Ifenprodil exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM) [1]. Ifenprodil is an α1 adrenergic receptor antagonist. Ifenprodil inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil has reliable inhibitory effects against A/H1N1 strains (EC50 of 6.6 µM) . Ifenprodil has neuroprotective, anticonvulsant and antinociceptive effects. Ifenprodil can be used for the study of cerebrovascular diseases and peripheral arterial obliterative disease[2][4].

• Product Name Alternative :

  NP-120; RC-61-91

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H332

• Target :

  Adrenergic Receptor; Calcium Channel; iGluR; Influenza Virus; Potassium Channel

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Infection; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/ifenprodil.html

• Purity :

  99.94

• Solubility :

  DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  OC(C1=CC=C(O)C=C1)C(C)N(CC2)CCC2CC3=CC=CC=C3

• Molecular Formula :

  C21H27NO2

• Molecular Weight :

  325.44

• Precautions :

  H302, H312, H332

• References & Citations :

  [1]Williams K, et al. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol. 1993 Oct;44 (4) :851-9.|[2]Kobayashi T, et al. Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil. Neuropsychopharmacology. 2006 Mar;31 (3) :516-24.|[3]Chen YW, et al. Ifenprodil for prolonged spinal blockades of motor function and nociception in rats. Pharmacol Rep. 2016 Apr;68 (2) :357-62.|[4]Jang Y, et al. In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus. Viruses. 2020 May 25;12 (5) :581.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Citation 01 :

  Chemosphere. 2019 Aug:229:618-630.|Heliyon. 2023 May 29;9 (6) :e16631.|Life Sci. 2022 Apr 15:295:120419.|Neurosci Bull. 2020 Feb;36 (2) :153-164.|Antimicrob Agents Chemother. 2024 Nov 6;68 (11) :e0103524.|Cell Rep. 2025 May 14;44 (5) :115712.|Chemosphere. 2019 Aug:229:618-630.|Eur J Pharmacol. 2023 Dec 15:961:176174.|Eur J Pharmacol. 2024 Jul 25:176860.|Exp Brain Res. 2023 Dec;241 (11-12) :2735-2750.|Pharmaceuticals (Basel) . 2024 Sep 19;17 (9) :1234.

• CAS Number :

  [23210-56-2]